HUP0300619A3 - Pharmaceutical compositions containing oxadiazole derivatives having anticancer effects - Google Patents
Pharmaceutical compositions containing oxadiazole derivatives having anticancer effectsInfo
- Publication number
- HUP0300619A3 HUP0300619A3 HU0300619A HUP0300619A HUP0300619A3 HU P0300619 A3 HUP0300619 A3 HU P0300619A3 HU 0300619 A HU0300619 A HU 0300619A HU P0300619 A HUP0300619 A HU P0300619A HU P0300619 A3 HUP0300619 A3 HU P0300619A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- oxadiazole derivatives
- anticancer effects
- containing oxadiazole
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000120234 | 2000-04-21 | ||
| PCT/JP2001/003214 WO2001083463A1 (fr) | 2000-04-21 | 2001-04-16 | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0300619A2 HUP0300619A2 (hu) | 2003-07-28 |
| HUP0300619A3 true HUP0300619A3 (en) | 2006-02-28 |
Family
ID=18631080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300619A HUP0300619A3 (en) | 2000-04-21 | 2001-04-16 | Pharmaceutical compositions containing oxadiazole derivatives having anticancer effects |
Country Status (16)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| WO2005012268A1 (ja) | 2003-07-30 | 2005-02-10 | Shionogi & Co., Ltd. | イソオキサゾール環を有するスルホンアミド誘導体 |
| CN101043887A (zh) * | 2004-10-22 | 2007-09-26 | 默克公司 | 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物 |
| US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
| GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP4383525B2 (ja) | 2006-05-09 | 2009-12-16 | ファイザー・プロダクツ・インク | シクロアルキルアミノ酸誘導体およびその医薬組成物 |
| KR100783585B1 (ko) | 2006-08-22 | 2007-12-07 | 한국생명공학연구원 | 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제 |
| EP2182809B1 (en) | 2007-08-27 | 2018-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
| RU2010128006A (ru) * | 2007-12-10 | 2012-01-20 | Актелион Фармасьютиклз Лтд (Ch) | Производные тиофена в качестве агонистов sipi/edgi |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| RU2415845C1 (ru) * | 2009-10-14 | 2011-04-10 | Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) | Сульфонные производные 2-нитро-2-(3-арил-1,2,4-оксадиазол-5-ил)этана, обладающие противолепрозной и противотуберкулезной активностью |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| CN103450167A (zh) * | 2012-05-28 | 2013-12-18 | 南京大学 | 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| CA3159378A1 (en) | 2019-10-31 | 2021-05-06 | ESCAPE Bio, Inc. | Solid forms of an s1p-receptor modulator |
| CN113264899B (zh) * | 2021-04-09 | 2022-06-14 | 台州学院 | 一种1，3，5-噁二嗪类化合物及其制备和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK262000A3 (en) | 1997-07-22 | 2001-01-18 | Shionogi & Co | Therapeutic or prophylactic agent for glomerulopathy |
| WO2000015213A1 (fr) | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Agent de prevention ou de traitement de l'insuffisance cardiaque congestive |
-
2001
- 2001-04-16 WO PCT/JP2001/003214 patent/WO2001083463A1/ja not_active Application Discontinuation
- 2001-04-16 CN CNB018112404A patent/CN1199956C/zh not_active Expired - Fee Related
- 2001-04-16 AU AU2001246916A patent/AU2001246916B2/en not_active Ceased
- 2001-04-16 US US10/257,917 patent/US6720343B2/en not_active Expired - Fee Related
- 2001-04-16 KR KR1020027013969A patent/KR100542780B1/ko not_active Expired - Fee Related
- 2001-04-16 AU AU4691601A patent/AU4691601A/xx active Pending
- 2001-04-16 CA CA002406685A patent/CA2406685C/en not_active Expired - Fee Related
- 2001-04-16 MX MXPA02010325A patent/MXPA02010325A/es active IP Right Grant
- 2001-04-16 PL PL359415A patent/PL203161B1/pl not_active IP Right Cessation
- 2001-04-16 JP JP2001580892A patent/JP3974781B2/ja not_active Expired - Fee Related
- 2001-04-16 BR BR0110211-7A patent/BR0110211A/pt not_active IP Right Cessation
- 2001-04-16 RU RU2002130247/04A patent/RU2275371C2/ru not_active IP Right Cessation
- 2001-04-16 EP EP01919938A patent/EP1277744A4/en not_active Withdrawn
- 2001-04-16 HU HU0300619A patent/HUP0300619A3/hu unknown
- 2001-04-19 TW TW090109406A patent/TWI294877B/zh not_active IP Right Cessation
-
2002
- 2002-10-15 ZA ZA200208307A patent/ZA200208307B/xx unknown
- 2002-10-18 NO NO20025035A patent/NO324868B1/no not_active IP Right Cessation
-
2003
- 2003-12-10 US US10/730,946 patent/US20040122066A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL203161B1 (pl) | 2009-08-31 |
| NO20025035D0 (no) | 2002-10-18 |
| WO2001083463A1 (fr) | 2001-11-08 |
| EP1277744A4 (en) | 2007-07-11 |
| CN1436179A (zh) | 2003-08-13 |
| PL359415A1 (en) | 2004-08-23 |
| US20040122066A1 (en) | 2004-06-24 |
| NO324868B1 (no) | 2007-12-17 |
| CN1199956C (zh) | 2005-05-04 |
| CA2406685A1 (en) | 2002-10-17 |
| JP3974781B2 (ja) | 2007-09-12 |
| EP1277744A1 (en) | 2003-01-22 |
| HUP0300619A2 (hu) | 2003-07-28 |
| TWI294877B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2008-03-21 |
| BR0110211A (pt) | 2003-06-03 |
| AU2001246916B2 (en) | 2004-10-07 |
| RU2275371C2 (ru) | 2006-04-27 |
| KR20030019357A (ko) | 2003-03-06 |
| NO20025035L (no) | 2002-12-19 |
| AU4691601A (en) | 2001-11-12 |
| ZA200208307B (en) | 2003-10-15 |
| US20030203940A1 (en) | 2003-10-30 |
| MXPA02010325A (es) | 2003-04-25 |
| KR100542780B1 (ko) | 2006-01-11 |
| CA2406685C (en) | 2006-10-31 |
| US6720343B2 (en) | 2004-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2358583B (en) | Pharmaceutical compositions | |
| IL150447A0 (en) | Pharmaceutical compositions containing entecavir | |
| HUP0300582A3 (en) | Pharmaceutical compositions | |
| AU6219601A (en) | Pharmaceutical compositions | |
| HUP0200530A3 (en) | Anticancer compositions containing hydroximatairesinol | |
| HUP0300619A3 (en) | Pharmaceutical compositions containing oxadiazole derivatives having anticancer effects | |
| AU2001271037A1 (en) | Pharmaceutical compositions containing dds compounds | |
| GB0009584D0 (en) | Pharmaceutical compositions | |
| HUP0400644A3 (en) | Pharmaceutical compositions containing aspirin | |
| IL137363A (en) | Pharmaceutical compositions containing mupirocin | |
| AU8576801A (en) | Pharmaceutical compositions | |
| HUP0400553A3 (en) | Pharmaceutical compositions | |
| AU2001246916A1 (en) | Oxadiazole derivatives having anticancer effects | |
| HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them | |
| AU1390002A (en) | Pharmaceutical compositions | |
| GB0008485D0 (en) | Pharmaceutical compositions | |
| HUP0303204A3 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing them | |
| GB0009613D0 (en) | Pharmaceutical compositions | |
| IL156372A0 (en) | Carbazole derivatives and pharmaceutical compositions containing the same | |
| AU4834101A (en) | N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them | |
| IL156174A (en) | 1,2,4-oxadiazole derivatives and pharmaceutical compositions containing them | |
| IL149470A0 (en) | Pharmaceutical compositions containing carboxamidoadenosine derivatives | |
| AU2001239349A1 (en) | Oral pharmaceutical compositions containing n-sulphonylindoline derivatives | |
| PT1326607E (pt) | Composições farmacêuticas contendo ácidos oxapenemo-3- carboxílicos | |
| GB0018321D0 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU Representative=s name: DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEG, HU |
|
| FH92 | Termination of representative |
Representative=s name: BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVI, HU |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |